Susquehanna International Group, LLP Alx Oncology Holdings Inc Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.81 - $8.13 $199,643 - $896,739	-110,300 Reduced 67.92%	52,100 $94,000
Q2 2024 Aug 15, 2024	BUY	$5.84 - $17.56 $407,632 - $1.23 Million	69,800 Added 75.38%	162,400 $979,000
Q1 2024 May 07, 2024	SELL	$10.95 - $16.79 $977,834 - $1.5 Million	-89,300 Reduced 49.09%	92,600 $1.03 Million
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $771,523 - $2.47 Million	160,400 Added 746.05%	181,900 $2.71 Million
Q3 2023 Nov 14, 2023	BUY	$4.19 - $7.35 $2,514 - $4,410	600 Added 2.87%	21,500 $103,000
Q2 2023 Aug 11, 2023	BUY	$4.37 - $9.56 $45,885 - $100,380	10,500 Added 100.96%	20,900 $156,000
Q1 2023 May 16, 2023	SELL	$4.52 - $11.71 $28,927 - $74,944	-6,400 Reduced 38.1%	10,400 $47,000
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $138,846 - $189,070	-14,600 Reduced 46.5%	16,800 $189,000
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $107,813 - $198,334	-13,100 Reduced 29.44%	31,400 $300,000
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $186,713 - $616,882	31,700 Added 247.66%	44,500 $360,000
Q1 2022 May 16, 2022	SELL	$13.65 - $22.06 $429,975 - $694,890	-31,500 Reduced 71.11%	12,800 $216,000
Q3 2021 Nov 15, 2021	BUY	$52.51 - $80.91 $1.27 Million - $1.95 Million	24,100 Added 119.31%	44,300 $3.27 Million
Q2 2021 Aug 11, 2021	BUY	$52.2 - $75.23 $99,180 - $142,937	1,900 Added 10.38%	20,200 $1.11 Million
Q1 2021 May 17, 2021	BUY	$62.84 - $87.68 $754,080 - $1.05 Million	12,000 Added 190.48%	18,300 $1.35 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $214,893 - $707,238	6,300 New	6,300 $543,000

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $52.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.